597 related articles for article (PubMed ID: 28945842)
1. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
4. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
5. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
7. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
8. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
9. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
10. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
11. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.
Brouwer TP; Vahrmeijer AL; de Miranda NFCC
Cell Oncol (Dordr); 2021 Apr; 44(2):261-278. PubMed ID: 33710604
[TBL] [Abstract][Full Text] [Related]
15. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
Bazhin AV; Shevchenko I; Umansky V; Werner J; Karakhanova S
Cancer Immunol Immunother; 2014 Jan; 63(1):59-65. PubMed ID: 24129765
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy.
Gleeson FC; Levy MJ; Jackson RA; Murphy SJ; Halling KC; Kipp BR; Graham RP; Zhang L
Pancreatology; 2020 Mar; 20(2):229-238. PubMed ID: 31831392
[TBL] [Abstract][Full Text] [Related]
18. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
[TBL] [Abstract][Full Text] [Related]
19. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
20. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]